Mouse Monoclonal MCL-1 Antibody

MCL-1 (Myeloid Cell Leukemia 1) is a pro-survival protein in the BCL-2 family that regulates apoptosis by binding pro-apoptotic proteins like BIM and BAX. Overexpression of MCL-1 is linked to cancer progression, resistance to chemotherapy, and poor prognosis in various malignancies, including hematologic cancers and solid tumors. Targeting MCL-1 has emerged as a therapeutic strategy to restore apoptosis in cancer cells. MCL-1 antibodies, either as standalone agents or in combination therapies, aim to inhibit its anti-apoptotic function. These antibodies typically block MCL-1 interactions with pro-apoptotic partners or target it for degradation. Challenges include MCL-1's short half-life, structural complexity, and its essential role in normal tissues (e.g., heart, liver), raising toxicity concerns. Recent advances in structural biology have enabled the design of selective inhibitors, including monoclonal antibodies and small molecules. Preclinical studies show promise, particularly in synergistic approaches with BH3 mimetics (e.g., venetoclax) or conventional chemotherapies. However, clinical development remains cautious due to on-target toxicities observed in early trials. Ongoing research focuses on optimizing binding specificity, delivery methods, and combination regimens to maximize efficacy while minimizing adverse effects.